Phillip J. Daschner

Phillip J. Daschner

Auto-generated profile, based on publicly available information

Phillip J. Daschner

Division of Cancer Biology, National Cancer Institute, Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in Biologicals
Verified
Journal Article
Closed access
IBIlia Belotserkovsky
Ilia Belotserkovsky
LSLisa M. Stabryla
Lisa M. Stabryla
MHMonique Hunter
Monique Hunter
JAJessica Allegretti
Jessica Allegretti
BCBenjamin J. Callahan
Benjamin J. Callahan
SNShawn Novick
Shawn Novick

21 October 2020 in Colorectal Cancer
Verified
Journal Article
Open access
LBLaura Brockway-Lunardi
Laura Brockway-Lunardi
SNStefanie Nelson
Stefanie Nelson
APArun R Pandiri
Arun R Pandiri
JTJames V Tricoli
James V Tricoli
AUAsad Umar
Asad Umar
PDPhillip J Daschner
Phillip J Daschner

24 January 2022 in Biologicals
Verified
Journal Article
Closed access
SSStephanie L. Servetas
Stephanie L. Servetas
PDPhillip J. Daschner
Phillip J. Daschner
CGCyril Guyard
Cyril Guyard
VTVincent Thomas
Vincent Thomas
HAHerve Affagard
Herve Affagard
PSPhilippe Sabot
Philippe Sabot

1 April 2017 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
PDPhillip J. Daschner
Phillip J. Daschner
MGMatthew B. Grisham
Matthew B. Grisham
MEMichael Graham Espey
Michael Graham Espey

5 October 2022 in Journal of the Academy of Nutrition and Dietetics
Verified
Journal Article
Closed access
PDPhillip J. Daschner
Phillip J. Daschner
SRSharon Ross
Sharon Ross
HSHarold Seifried
Harold Seifried
AKAmit Kumar
Amit Kumar
RFRoberto Flores
Roberto Flores

2 July 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
MCMaria. Constanza Camargo
Maria. Constanza Camargo
CAChristian C Abnet
Christian C Abnet
JDJeremy Davis
Jeremy Davis
CMCecilia Monge
Cecilia Monge
TLTram Kim Lam
Tram Kim Lam
EREllen Richmond
Ellen Richmond
Gastric cancer remains a major health challenge globally. In the United States, gastric cancer outcomes remain poor, with well-documented disparities in incidence and mortality. In 2024, the US National Cancer Institute convened a Think Tank on Advancing Gastric Cancer Prevention, with participation of over 200 global leaders from academia, clinical practice, and industry as well as patient advocates to exchange knowledge, lived experiences, and discuss future research opportunities. This commentary summarizes the Think Tank presentations and discussions of key existing evidence as well as challenges and opportunities for the prevention and control of this preventable disease. Primary prevention discussions focused on the use of the screen-and-treat strategy for Helicobacter pylori eradication. Secondary prevention discussions included endoscopic screening and surveillance of advanced gastric precancerous lesions. Primary conclusions for gastric cancer prevention and control included the need for (1) developing large-scale study resources that optimize the ability to conduct research with potential clinical translation applications; (2) strengthening and building community-public health-academic partnerships to enhance research; and (3) leveraging evidence-based strategies developed in high-risk East Asian countries to high-risk subgroups in low- and moderate-risk countries including the United States. There was overwhelming agreement that given the current state of gastric cancer incidence and survival in the United States, novel strategies to control the carcinogenic effects of H. pylori and to improve detection of precursors are the key to substantially reducing the burden of this disease.